NY-WUNDERKIND
6.3.2023 06:02:36 CET | Business Wire | Press release
Wunderkind, the leading performance marketing solution that delivers guaranteed revenue and performance for brands, publishers and advertisers, announced the appointment of Bill Ingram, a proven marketing technology leader, as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005559/en/
Former Adobe and Cheetah Digital executive Bill Ingram named CEO of leading performance marketing solution Wunderkind. (Photo: Business Wire)
Ingram brings over 30 years of experience scaling tech start-ups, leading enterprise SaaS organization advancement, and driving product development and growth. Before joining Wunderkind, Ingram served as President and Chief Product Officer at Cheetah Digital, driving the global innovation and advancement of next generation B2C marketing automation solutions. Previously, Ingram was Vice President and General Manager at Adobe, overseeing the organization’s Analytics Cloud worldwide business for over 10 years. Ingram previously held leadership roles with several SaaS organizations, including Sybase and Omniture, which was acquired by Adobe for $1.8B.
In his role as CEO, Ingram will establish and drive Wunderkind’s strategic direction and product expansion in support of increasing customer engagement for the world’s leading brands. He will focus on taking Wunderkind’s products and services to new levels, while maintaining an industry leading revenue guarantee. Additionally, he will work to advance Wunderkind’s product suite for leading publishers to further engage consumers in an impactful, non-intrusive way that fosters increased brand visibility and qualified engagement. Ingram will lead the team towards ensuring Wunderkind’s solutions continue to help advertisers reach their priority audiences while delivering a quality user experience across a network of premium publishers. Furthermore, he will concentrate on leading the Wunderkind team to eclipsing its over 34% year-over-year revenue increase realized last year.
“Wunderkind has achieved exponential growth by delivering undeniable marketing performance and increased revenue for the world’s most renowned eCommerce brands, who are constantly competing to attract, retain and convert valued customers,” said CEO Bill Ingram. “Wunderkind has proven that channels once perceived as top- and middle-of-funnel can be transformed into significant revenue drivers. I look forward to leading the company’s all-star team as we embark upon a new chapter of strategic innovation and proliferation.”
Ingram’s appointment comes as Wunderkind is poised for continued acceleration in 2023 on the heels of major milestones in 2022, which included: a $76M in Series C financing led by Neuberger Berman; 34% year-over-year revenue gain; and the opening of offices in Australia, Canada, and the Netherlands to further its global reach.
“In a fiercely competitive eCommerce landscape, marketers are under tremendous pressure to deliver verifiable ROI for every dollar spent. Wunderkind's pioneering solutions stand superior to all other solutions in our industry, assisting countless brands in driving provable revenue while building lasting customer loyalty,” said Stephen Collins, Wunderkind’s Board Chairman. “We are confident that Bill’s proven leadership, industry expertise, and success in scaling global technology organizations will realize a new era of growth and success for Wunderkind’s customers, partners and employees alike.”
During the 2022 holiday season, despite a challenging macroeconomic climate, Wunderkind was pivotal in helping its clients achieve more than $1B in directly attributable revenue. The company recently added a host of premium publishers and global retailers to its client roster, including; Rag & Bone, Refinery29, JLo Beauty, Uniqlo, e.l.f. cosmetics, Swatch, Outdoor Voices, See's Candy.
About Wunderkind
Wunderkind is a leading performance marketing solution that drives guaranteed revenue for brands, publishers, and advertisers. As first-party data becomes central to efficient growth, Wunderkind enables brands to identify their website visitors on an individual level and deliver more of their highest-performing, one-to-one messages through websites, emails, texts, and ads than otherwise possible. Wunderkind drives $5 billion annually in directly attributable revenue for brands like Uniqlo, Refinery29, Sonos, and HelloFresh, often ranking as a top three performance channel in their own analytics platforms. Discover how Wunderkind can drive efficient growth for your brand by visiting wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
